Search results for "NONALCOHOLIC FATTY LIVER DISEASE"

showing 10 items of 139 documents

2019

Background: Physical inactivity is a major risk factor for nonalcoholic fatty liver disease (NAFLD). Exercise-based prevention interventions for improving cardiorespiratory fitness are a recommended complementary treatment for NAFLD. Achievement of minimally effective physical activity to improve cardiorespiratory fitness among patients typically involves high personal and financial expenses in face-to-face settings. We designed an eHealth approach for patients with NAFLD to improve the cardiorespiratory fitness and report the first results of the HELP (Hepatic Inflammation and Physical Performance in Patients With NASH [nonalcoholic steatohepatitis]) study. Objective: We aimed to assess th…

medicine.medical_specialty020205 medical informaticsbusiness.industryFatty liverPsychological interventionVO2 maxHealth InformaticsCardiorespiratory fitness02 engineering and technologymedicine.diseaseEndurance trainingNonalcoholic fatty liver disease0202 electrical engineering electronic engineering information engineeringmedicinePhysical therapyRisk factorAdverse effectbusinessJournal of Medical Internet Research
researchProduct

Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-ana…

2020

Background Cholangiocarcinoma is a cancer with poor prognosis. The detection of risk factors is fundamental to identify subjects at higher risk of cholangiocarcinoma. Nonalcoholic fatty liver disease (NAFLD) represents a leading cause of chronic liver disease worldwide. Recent data suggested that NAFLD increases the risk of cholangiocarcinoma development. However, it is necessary to better explain the strength of association between NAFLD and cholangiocarcinoma. Methods A systematic research of current case-control, cohort, clinical trial and meta-analysis on the main electronic databases was made. A recent systematic review was recognized. We performed cumulative meta-analyses with sensiti…

medicine.medical_specialtyChronic liver diseasedigestive systemGastroenterologyCholangiocarcinoma03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineHumansIntrahepatic CholangiocarcinomaHepatologybusiness.industryConfoundingLiver NeoplasmsGastroenterologyOdds ratiomedicine.diseasedigestive system diseasesConfidence intervalClinical trialBile Ducts IntrahepaticBile Duct Neoplasms030220 oncology & carcinogenesisMeta-analysisliver Intrahepatic Cholangiocarcinoma extrahepatic Cholangiocarcinoma030211 gastroenterology & hepatologybusiness
researchProduct

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association wi…

2016

Non-alcoholic fatty liver disease (NAFLD) comprises a series of histologically lesions similar to those induced by alcohol consumption in people with very little or no liver damage. The importance of NAFLD is its high prevalence in the Western world and, from the point of view of the liver, in its gradual progression from steatosis to steatohepatitis, cirrhosis, and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with acceleration of arteriosclerosis and events related to it, being the main cause of its morbidity and mortality. This review, updated to January 2016, consists of two parts, with the first part analysing the associa…

medicine.medical_specialtyCirrhosisDisease030204 cardiovascular system & hematologyGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseaseMedicineHumansGeneral Environmental Sciencebusiness.industryFatty liverGeneral Engineeringnutritional and metabolic diseasesArteriosclerosismedicine.diseaseAtherosclerosisdigestive system diseasesCardiovascular DiseasesDisease ProgressionGeneral Earth and Planetary Sciences030211 gastroenterology & hepatologySteatohepatitisSteatosisbusinessLiver cancerClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.

2016

Disease nonalcoholic fatty liver disease (NAFLD) comprises a series of histologically similar to those induced by alcohol consumption in people with very little or no liver damage same. The importance of NAFLD is its high prevalence in our Western societies, from the point of view liver in its progressive evolution from steatosis to steatohepatitis, cirrhosis and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with accelerated atherosclerosis and cardiovascular events, the leading cause of morbidity and mortality. This updated January 2016 revision consists of two parts. In this second part, the treatment of NAFLD and its influe…

medicine.medical_specialtyCirrhosisDiseaseGastroenterologyLiver diseaseNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicineAnimalsHumansGeneral Environmental Sciencebusiness.industryGeneral EngineeringArteriosclerosismedicine.diseaseAtherosclerosisdigestive system diseasesCardiovascular DiseasesDisease ProgressionGeneral Earth and Planetary SciencesSteatosisSteatohepatitisLiver cancerbusinessClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation

2019

Background & Aims Chronic liver disease has negative effects on health-related quality of life (HRQL). We analyzed data from the European non-alcoholic fatty liver disease (NAFLD) registry to assess the effects of NAFLD on HRQL. Methods We collected data from 304 patients (mean age, 52.3 ± 12.9 years) with histologically defined NAFLD enrolled prospectively into the European NAFLD Registry in Germany, the United Kingdom, and Spain. The chronic liver disease questionnaire (CLDQ) was completed within 6 months of liver biopsy collection. Results The mean CLDQ overall score was 5.0 ± 1.2, with the lowest score in the category fatigue (4.3 ± 1.6) and the highest scores for activity (5.4 ± 1.4). …

medicine.medical_specialtyCirrhosisHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologymedicine.diseaseChronic liver diseaseGastroenterology3. Good health03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisDiabetes mellitusLiver biopsyInternal medicineNonalcoholic fatty liver diseasemedicine030211 gastroenterology & hepatologyPatient-reported outcomebusinessBody mass indexClinical Gastroenterology and Hepatology
researchProduct

A Cholestatic Pattern Predicts Liver-Related Events in Patients with Nonalcoholic Fatty Liver Disease

2021

Background & Aims: Liver test alteration patterns can be categorized as: predominantly hepatocellular(H), with an ALT/ALP ratio>5; predominantly cholestatic pattern(C) with a ratio 55 years(HR2.55,95%C.I.1.17-5.54;p=0.01), platelets<150,000/mmc(HR0.14,95%C.I.0.06-0.32;p<0.001), albumin<4g/L(HR0.62,95%C.I.0.35-1.08;p=0.09), C vs M pattern(HR7.86,95%C.I.1.03-60.1;p=0.04), C vs H pattern(HR12.1,95% C.I.1.61-90.9;p=0.01) and fibrosis F3-F4(HR35.8,95%C.I.4.65-275.2;p<0.001) were independent risk factors for LRE occurrence. C vs M pattern(HR14.3,95%C.I.1.90-105.6;p=0.008) and C vs H pattern(HR15.6,95%C.I. 2.10-115.1;p=0.0068) were confirmed independently associated with LRE occurrence in the vali…

medicine.medical_specialtyCirrhosisbusiness.industryProportional hazards modelmedicine.diseaseGastroenterologyLiver diseaseCholestasisMetaplasiaInternal medicineCohortNonalcoholic fatty liver diseaseMedicineIn patientmedicine.symptombusinessSSRN Electronic Journal
researchProduct

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.

2020

Nonalcoholic fatty liver disease (NAFLD) is a clinical condition that encompasses various forms of liver damage not caused by chronic alcohol consumption. In the absence of other etiologies, it ranges from ste- atosis to nonalcoholic steatohepatitis and cirrhosis. The prevalence of NAFLD has considerably increased over the last years owing to the current lifestyle (unhealthy diet and sedentarism). Besides, it is associated with metabolic risk factors such as obesity, arterial hypertension, dyslipidemia, and type 2 diabetes. Given the poor prognosis of patients with advanced NAFLD, a practical therapeutic approach is necessary to halt its natural history. However, no licensed drugs have been…

medicine.medical_specialtyCirrhosisbusiness.industrynutritional and metabolic diseasesDiseaseType 2 diabetesComorbiditymedicine.diseaseObesitydigestive system diseasesArterial hypertension Dyslipidemia Nonalcoholic fatty liver disease Type 2 diabetes Comorbidity Humans Obesity Weight Loss Diabetes Mellitus Type 2 Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus Type 2Weight lossNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseWeight LossInternal MedicinemedicineHumansObesitymedicine.symptomSteatosisbusinessDyslipidemiaPolish archives of internal medicine
researchProduct

A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease

2021

Patients with nonalcoholic fatty liver disease (NAFLD) may show mild cognitive impairment (MCI). The neurological functions affected remain unclear. The aims were to: (1) Characterize the neuropsychological alterations in NAFLD patients; (2) assess the prevalence of impairment of neurological functions evaluated; (3) develop a new score for sensitive and rapid MCI detection in NAFLD; (4) assess differences in MCI features between patients with nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH); and (5) compare neuropsychological alterations in NAFLD patients with cirrhotic patients with MCI. Fifty-nine NAFLD patients and 53 controls performed psychometric tests assessin…

medicine.medical_specialtyCirrhosisneurological impairmentpsychometric scoreGastroenterologybehavioral disciplines and activitiesdigestive systemArticle03 medical and health sciences0302 clinical medicineInternal medicineNAFLDNonalcoholic fatty liver diseasemedicineMemory spanHepatic encephalopathyPsychomotor learningbusiness.industryFatty liverRNeuropsychologyNASHnutritional and metabolic diseasesGeneral Medicinemedicine.diseasepsychometric score; NAFLD; NAFL; NASH; neurological impairmentdigestive system diseasesNAFLMedicine030211 gastroenterology & hepatologybusiness030217 neurology & neurosurgeryStroop effectJournal of Clinical Medicine
researchProduct

Endothelial dysfunction in morbid obesity.

2013

Morbid obesity is a chronic multifunctional disease characterized by an accumulation of fat. Epidemiological studies have shown that obesity is associated with cardiovascular and metabolic disorders. Endothelial dysfunction, as defined by an imbalance between relaxing and contractile endothelial factors, plays a central role in the pathogenesis of these cardiometabolic diseases. Diminished bioavailability of nitric oxide (NO) contributes to endothelial dysfunction and impairs endothelium- dependent vasodilatation. But this is not the only mechanism that drives to endothelial dysfunction. Obesity has been associated with a chronic inflammatory process, atherosclerosis, and oxidative stress. …

medicine.medical_specialtyEndotheliumInflammationVasodilationDiseaseNitric OxideCoronary artery diseaseInternal medicineDiabetes mellitusDrug DiscoveryNonalcoholic fatty liver diseaseWeight LossMedicineAnimalsHumansEndothelial dysfunctionPharmacologyInflammationbusiness.industrymedicine.diseaseAtherosclerosisObesity MorbidVasodilationOxidative Stressmedicine.anatomical_structureEndocrinologyCardiovascular DiseasesEndothelium Vascularmedicine.symptombusinessCurrent pharmaceutical design
researchProduct

A human hepatocellular in vitro model to investigate steatosis

2006

The present study was designed to define an experimental model of hepatocellular steatosis with a fat overaccumulation profile in which the metabolic and cytotoxic/apoptotic effects could be separated. This was accomplished by defining the experimental conditions of lipid exposure that lead to significant intracellular fat accumulation in the absence of overt cytotoxicity, therefore allowing to differentiate between cytotoxic and apoptotic effects. Palmitic (C16:0) and oleic (Cl 8: 1) acids are the most abundant fatty acids (FFAs) in liver triglycerides in both normal subjects and patients with nonalcoholic fatty liver disease (NAFLD). Therefore, human hepatocytes and HepG2 cells were incub…

medicine.medical_specialtyHepG2Carcinoma HepatocellularCell SurvivalPalmitic AcidApoptosisBiologyFatty Acids NonesterifiedIn Vitro TechniquesToxicologyfatty acidscellular steatosisPalmitic acidchemistry.chemical_compoundInternal medicineCell Line TumorNonalcoholic fatty liver diseasemedicineHumansCytotoxicityDose-Response Relationship DrugapoptosisGeneral Medicinemedicine.diseaseFatty LiverDose–response relationshipmedicine.anatomical_structureEndocrinologychemistryBiochemistryApoptosisNeutral RedHepatocyteHepatocyteslipids (amino acids peptides and proteins)hepatocytesSteatosisIntracellularOleic Acid
researchProduct